Sedana Medical submits IND for US clinical trials

STOCKHOLM, Nov. 24, 2021 /PRNewswire/ -- Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), with the aim to commence its phase III pivotal clinical trials with its Sedaconda products in the United States.

Sedana Medical is aiming for a combination registration of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane) for inhaled sedation of mechanically ventilated patients in intensive care. Provided that the IND is approved, the company is planning to commence patient recruitment at the turn of Q1/Q2 2022, with the objective to obtain US approval in 2024.

"We are happy to announce that we have now submitted the IND to the FDA and the preparations for our clinical program in the United States are progressing according to plan. The US market represents the largest commercial opportunity for Sedana Medical and we are looking forward to bringing our Sedaconda products to intensive care patients in the US. We have recruited many of the most reputable centers for our US clinical trials and are eager to commence patient enrollment" said Johannes Doll, CEO of Sedana Medical.

Sedana Medical aims to conduct two multicenter, randomized controlled, assessor-blinded clinical trials to confirm efficacy and safety. The number of patients in both trials combined will be around 500. The study design is similar to the SED-001 trial that was successfully completed in Europe and formed the basis for the European approval earlier this year. The primary endpoint in each study will be to show that Sedaconda (isoflurane), administered via Sedaconda ACD, is effective and non-inferior to propofol for sedation of mechanically ventilated patients in the intensive care unit. The secondary endpoints relate to opioid requirements, spontaneous breathing, wake-up time and cognitive recovery.

For additional information, please contact:
Johannes Doll, CEO, +46 76 303 66 66
Susanne Andersson, CFO, +46 73 066 89 04
ir@sedanamedical.com

Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.

About Sedana Medical

Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient's life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.

Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.

Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sedana-medical/r/sedana-medical-submits-ind-for-us-clinical-trials,c3459597

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/sedana-medical-submits-ind-for-us-clinical-trials-301431447.html

SOURCE Sedana Medical

Company Codes: ISIN:SE0009947534, Stockholm:SEDANA